You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 19, 2025

~ Buy the CROSPOVIDONE Drug Excipient Business Development Opportunity Report, 2024 PDF Report in the Report Store ~

Drugs Containing Excipient (Inactive Ingredient) CROSPOVIDONE


✉ Email this page to a colleague

« Back to Dashboard


Branded drugs containing CROSPOVIDONE excipient, and estimated key patent expiration / generic entry dates

CompanyTradenameIngredientNDCExcipientPotential Generic Entry
ER Squibb & Sons LLC BARACLUDE entecavir 0003-1611 CROSPOVIDONE
Eli Lilly and Company EVISTA raloxifene hydrochloride 0002-4184 CROSPOVIDONE
Eli Lilly and Company ZYPREXA olanzapine 0002-4112 CROSPOVIDONE
>Company>Tradename>Ingredient>NDC>Excipient>Potential Generic Entry
Showing 1 to 3 of 3 entries

Market Dynamics and Financial Trajectory for the Pharmaceutical Excipient: Crospovidone

Introduction

Crospovidone, a synthetic cross-linked polyvinylpyrrolidone (PVP), is a crucial excipient in the pharmaceutical industry, particularly in the formulation of orally disintegrating tablets (ODTs) and fast-dissolving dosage forms. Here, we delve into the market dynamics and financial trajectory of crospovidone, highlighting its growth drivers, market size, and future projections.

Market Size and Growth

The global superdisintegrants market, which includes crospovidone, was valued at USD 536.2 million in 2023 and is projected to grow at a CAGR of 5.3% from 2024 to 2030[1][4].

Crospovidone Segment

Within this market, the crospovidone segment holds a significant share. In 2023, crospovidone products accounted for 32.1% of the market, and this segment is expected to maintain its lead position and exhibit the fastest growth trajectory throughout the forecast period[1].

Growth Drivers

Several factors are driving the growth of the crospovidone market:

Expanding Generics Market

The increasing demand for generic drugs, which often utilize orally disintegrating tablets, is a major driver. The generics market's expansion is fueling the need for superdisintegrants like crospovidone[1][4].

Technological Advancements

Advancements in research and development (R&D) are leading to the creation of innovative superdisintegrants. These technological advancements are enhancing the performance of crospovidone, making it more desirable for pharmaceutical formulations[1].

Growing Geriatric and Pediatric Needs

The rising geriatric population and the increasing prevalence of dysphagia (swallowing difficulties) in pediatrics are driving the demand for ODTs and fast-dissolving dosage forms. Crospovidone plays a critical role in these formulations, improving patient compliance and medication adherence[1].

Regulatory Environment

Increased government oversight and stricter regulations within the pharmaceutical industry are driving the demand for safe and natural superdisintegrants. This focus on patient safety is creating opportunities for companies to develop innovative products, including crospovidone[1].

Market Segmentation

By Product

Crospovidone is one of the leading products in the superdisintegrants market. Its wide use in fast-disintegrating oral solid dosage forms is a key factor in its market dominance[4].

By Formulation

Tablets and capsules, which extensively use crospovidone, commanded a dominant market share of 62.3% in 2023. The widespread use of ODTs and fast-dissolving tablets among healthcare providers and patients is driving this segment[1][4].

By Region

  • North America: The U.S. superdisintegrants market, which includes crospovidone, dominated the North American market with a revenue share of 88.7% in 2023. This is attributed to proactive government initiatives, favorable healthcare policies, and a robust healthcare market[1].
  • Europe: Europe's superdisintegrants market is another lucrative region, driven by the increase in manufacturing capacity and the development of enhanced drug delivery processes[1].
  • Asia Pacific: The Asia Pacific region, particularly China and India, is expected to witness significant growth due to the expansion of the healthcare sector and a rapidly expanding manufacturing base[1][4].

Financial Trajectory

Current Market Value

The global superdisintegrants market, which includes crospovidone, was valued at USD 536.2 million in 2023[1].

Future Projections

The market is projected to grow at a CAGR of 5.3% from 2024 to 2030, reaching a significant value by the end of the forecast period. The crospovidone segment, in particular, is expected to exhibit the fastest growth trajectory due to its increasing preference in pharmaceutical formulations[1].

Competitive Landscape

Key players in the superdisintegrants market, including crospovidone, are focusing on strategic initiatives such as mergers and acquisitions, and partnerships to expand their customer base and gain a competitive edge. Companies like Merck KGaA, Ashland, BASF, and NIPPON SODA are among the leading players in this market[1].

Challenges and Opportunities

Safety and Quality Concerns

Despite the growth, safety and quality concerns are expected to challenge the market. However, these concerns also present opportunities for companies to develop safer and more natural superdisintegrants, aligning with regulatory requirements and patient safety needs[1][4].

Emerging Markets

The expansion of the pharmaceutical market in emerging countries such as China, India, and Brazil offers significant growth opportunities. These regions provide advantages such as low-cost manufacturing, increasing per capita income, and lenient regulatory environments[1][4].

Key Takeaways

  • The crospovidone market is driven by the expanding generics market, technological advancements, and growing needs for ODTs and fast-dissolving dosage forms.
  • The segment is expected to grow at the highest CAGR within the superdisintegrants market.
  • North America, Europe, and Asia Pacific are key regions driving the market growth.
  • Safety and quality concerns, along with emerging market opportunities, will shape the future of the crospovidone market.

FAQs

What is the current market size of the superdisintegrants market, and how is it projected to grow?

The global superdisintegrants market was valued at USD 536.2 million in 2023 and is projected to grow at a CAGR of 5.3% from 2024 to 2030[1].

Which segment dominates the superdisintegrants market?

The crospovidone segment dominates the market and is expected to maintain its lead position and exhibit the fastest growth trajectory throughout the forecast period[1].

What are the key drivers of the crospovidone market?

The key drivers include the expanding generics market, technological advancements, growing geriatric and pediatric needs, and a favorable regulatory environment[1][4].

Which regions are expected to witness significant growth in the superdisintegrants market?

North America, Europe, and Asia Pacific, particularly the U.S., UK, China, and India, are expected to witness significant growth[1][4].

What challenges might the crospovidone market face?

Safety and quality concerns are expected to challenge the market, although these also present opportunities for developing safer and more natural superdisintegrants[1][4].

Which companies are leading the superdisintegrants market?

Key players include Merck KGaA, Ashland, BASF, and NIPPON SODA[1].

Sources

  1. Grand View Research: Superdisintegrants Market Size, Share, Growth Report, 2030.
  2. Transparency Market Research: Africa Polyvinylpyrrolidone Market for Pharmaceutical and Cosmetic Industries.
  3. Biospace: Pharmaceutical Excipients Market Size to Surge to US$ 14.72 Billion by 2033.
  4. MarketsandMarkets: Superdisintegrants Market Growth Drivers & Opportunities.
  5. Market Research Pulse: Pharmaceutical Grade Crospovidone Market Trends, Scope And Forecast.

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.